Summarized in Table 3, the benefits of the addition of ICI agents Nivolumab, Pembrolizumab, and Durvalumab for B-cell NHLs have been variable, possibly related to the variability in CD3+/CD4+ TILs and tumor PD-L1 expression. Here, CD4 is linked to neoplasm.